DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Moreno-Aspitia A, Holmes E, Jackisch C. et al.
Updated results from the phase III ALTTO trial (BIG NCCTG/Alliance N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cance.
J Clin Oncol 2017;
35: 2-6
Access:
We do not assume any responsibility for the contents of the web pages of other providers.